BioNano Genomics Inc vs Digital Realty Trust, Inc. — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Digital Realty Trust, Inc. trades at $191.45 (market cap $70.61B). The key difference: Digital Realty Trust, Inc. is far larger — about 5169.1× BioNano Genomics Inc's market cap, and Digital Realty Trust, Inc. pays a 2.56% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | DLR | |
|---|---|---|
Market Cap | $13.66M | $70.61B |
Sector | Health | Real Estate |
52-Week High | $4.92 | $203.91 |
52-Week Low | $1.06 | $147.93 |
Enterprise Value | $16.26M | $89.32B |
Dividend Yield | — | 2.56% |
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Digital Realty (DLR) trades at $196.84, up 2.9% with bullish technical signals and strong analyst support. The stock shows robust fundamentals with revenue growth from $5.6B in 2024 to $6.1B in 2025 and net income reaching $1.31B. Recent Q2 2026 earnings beat expectations with $1.21 EPS versus $0.48 expected, driven by record leasing activity and AI-driven data center demand. The company maintains a 63.8% buy rating from analysts with a $216.56 consensus target.
DLR presents a compelling growth opportunity leveraging AI infrastructure demand, though premium valuation metrics (P/E 241.53, P/S 25.08) warrant caution. Key risks include high debt levels ($15.1B long-term) and cyclical tech spending. Current price near the $197 low target suggests limited downside with 10% upside to consensus target, supported by strong cash flow generation and dividend payments.
Trailing returns across standard periods
Latest headlines on both assets
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →Digital Realty owns and operates nearly 300 data centers worldwide. It has more than 35 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to cold shells, where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. Digital Realty has also moved more into the co-location business, increasingly serving enterprises and facilitating network connections. Digital Realty operates as a real estate investment trust.
Read more on DLR →